April 28, 2023 by admin aurigene Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRPα axis (CD47 antagonists)
April 28, 2023 by admin aurigene Preclinical evaluation of PD and efficacy of novel potent selective and orally bioavailable CDK12 covalent inhibitors in TNBC model (Covalent selective, CDK12i)
April 28, 2023 by admin aurigene Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516
April 28, 2023 by admin aurigene ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
April 28, 2023 by admin aurigene Antitumor activity of ODM-207, a novel BET bromodomain inhibitor, in nonclinical models of ER+ breast cancer as single agent and as a combination treatment
April 28, 2023 by admin aurigene Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy
April 28, 2023 by admin aurigene Safety, tolerability, pharmacokinetics and pharmacodynamics of AUR101, An RORγt inhibitor, in normal healthy volunteers
April 28, 2023 by admin aurigene Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313
